N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532
Online ISSN 1827-1715
Barberi S. 1, Bernardo L. 1, D’Auria E. 2, Ferrara F. 1, Tosi S. 1, Incorvaia C. 3, Buttafava S. 4, Frati F. 4, Ciprandi G. 5
1 Department of Pediatrics, Fatebenefratelli Hospital, Milan, Italy;
2 Department of Pediatrics, San Paolo Hospital, Milan, Italy;
3 Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, Italy;
4 Medical and Scientific Department, Stallergenes Italy, Milan, Italy;
5 Department of Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy
AIM: Allergic inflammation may promote respiratory infections (RI). House dust mite (HDM) sensitization is common in childhood. Allergen immunotherapy may cure allergy as it restores a physiological immune and clinical tolerance toward the causal allergen and exerts anti- inflammatory activity. This study retrospectively investigated whether 3 year high-dose HDM- sublingual immunotherapy (SLIT) could affect respiratory infections in children with allergic rhinitis.
METHODS: Globally, 33 HDM allergic children (18 males, mean age 9.3 years) were subdivided in 2 groups: 20 treated with symptomatic drugs alone (Group 1) and 13 by high-dose SLIT, titrated in mcg of major allergens (Group 2) for 3 years.
RESULTS: SLIT-treated children had significantly (p=0.01) less RI episodes (3.6) than symptomatically-treated children (5.4). In addition, SLIT-treated children had less fever (p<0.01) and took fewer medications, such as antibiotics (p<0.05) and fever-reducers (p<0.01), than symptomatically-treated children.
CONCLUSION: This preliminary study suggests that high-dose 3-year SLIT might lessen RI in allergic children.